EP3807254A4 - Composés hétérocycliques utiles dans le traitement d'une maladie - Google Patents

Composés hétérocycliques utiles dans le traitement d'une maladie Download PDF

Info

Publication number: EP3807254A4
Authority: EP; European Patent Office
Prior art keywords: disease; treatment; heterocyclic compounds; compounds useful; heterocyclic
Prior art date: 2018-06-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP19821626.9A

Other languages

German (de)

English (en)

Other versions

EP3807254A1 (fr

Inventor

Graham Beaton

Fabio C. Tucci

Satheesh B. Ravula

Chandravadan R. Shah

Suk Joong Lee

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

EPIGEN BIOSCIENCES Inc

Original Assignee

EPIGEN BIOSCIENCES Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-18

Filing date

2019-06-18

Publication date

2022-03-23

2018-06-18 Priority claimed from US16/010,755 external-priority patent/US10526298B2/en

2019-06-18 Application filed by EPIGEN BIOSCIENCES Inc filed Critical EPIGEN BIOSCIENCES Inc

2021-04-21 Publication of EP3807254A1 publication Critical patent/EP3807254A1/fr

2022-03-23 Publication of EP3807254A4 publication Critical patent/EP3807254A4/fr

Status Pending legal-status Critical Current

Links

201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
150000002391 heterocyclic compounds Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

EP19821626.9A 2018-06-18 2019-06-18 Composés hétérocycliques utiles dans le traitement d'une maladie Pending EP3807254A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16/010,755 US10526298B2 (en)	2013-03-15	2018-06-18	Heterocyclic compounds useful in the treatment of disease
PCT/US2019/037749 WO2019246109A1 (fr)	2018-06-18	2019-06-18	Composés hétérocycliques utiles dans le traitement d'une maladie

Publications (2)

Publication Number	Publication Date
EP3807254A1 EP3807254A1 (fr)	2021-04-21
EP3807254A4 true EP3807254A4 (fr)	2022-03-23

Family

ID=68985801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19821626.9A Pending EP3807254A4 (fr)	2018-06-18	2019-06-18	Composés hétérocycliques utiles dans le traitement d'une maladie

Country Status (5)

Country	Link
EP (1)	EP3807254A4 (fr)
JP (1)	JP7467361B2 (fr)
KR (1)	KR20210010635A (fr)
CA (2)	CA3104465A1 (fr)
WO (1)	WO2019246109A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW202342017A (zh)	2022-02-25	2023-11-01	美商洛子峰生物有限公司	用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012138648A1 (fr) *	2011-04-06	2012-10-11	Irm Llc	Compositions et procédés pour la modulation de récepteurs au lpa
US20130072449A1 (en) *	2011-03-20	2013-03-21	Intermune, Inc.	Lysophosphatidic acid receptor antagonists
WO2014145873A2 (fr) *	2013-03-15	2014-09-18	Epigen Biosciences, Inc.	Composés hétérocycliques utilisés pour le traitement de maladies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1258484E (pt) *	2000-02-18	2009-04-03	Kyowa Hakko Kirin Co Ltd	Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
US20040063738A1 (en)	2001-12-05	2004-04-01	Lahm George Philip	Substituted heterocyclic phthalic acid diamide arthropodicides
PL2029547T3 (pl)	2006-05-24	2010-09-30	Lilly Co Eli	Agoniści FXR
GB2470833B (en) *	2009-06-03	2011-06-01	Amira Pharmaceuticals Inc	Polycyclic antagonists of lysophosphatidic acid receptors
GB2474120B (en) *	2009-10-01	2011-12-21	Amira Pharmaceuticals Inc	Compounds as Lysophosphatidic acid receptor antagonists

2019
- 2019-06-18 EP EP19821626.9A patent/EP3807254A4/fr active Pending
- 2019-06-18 CA CA3104465A patent/CA3104465A1/fr active Pending
- 2019-06-18 WO PCT/US2019/037749 patent/WO2019246109A1/fr unknown
- 2019-06-18 KR KR1020217001002A patent/KR20210010635A/ko active Search and Examination
- 2019-06-18 JP JP2020570145A patent/JP7467361B2/ja active Active
- 2019-06-18 CA CA3046894A patent/CA3046894A1/fr not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130072449A1 (en) *	2011-03-20	2013-03-21	Intermune, Inc.	Lysophosphatidic acid receptor antagonists
WO2012138648A1 (fr) *	2011-04-06	2012-10-11	Irm Llc	Compositions et procédés pour la modulation de récepteurs au lpa
WO2014145873A2 (fr) *	2013-03-15	2014-09-18	Epigen Biosciences, Inc.	Composés hétérocycliques utilisés pour le traitement de maladies

Also Published As

Publication number	Publication date
CA3104465A1 (fr)	2019-12-26
WO2019246109A1 (fr)	2019-12-26
JP2021529733A (ja)	2021-11-04
CA3046894A1 (fr)	2019-12-18
KR20210010635A (ko)	2021-01-27
JP7467361B2 (ja)	2024-04-15
EP3807254A1 (fr)	2021-04-21

Legal Events

Date	Code	Title	Description
2019-12-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-01-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-03-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-04-21	17P	Request for examination filed	Effective date: 20201230
2021-04-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-04-21	AX	Request for extension of the european patent	Extension state: BA ME
2021-07-23	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40040026 Country of ref document: HK
2021-09-22	DAV	Request for validation of the european patent (deleted)
2021-09-22	DAX	Request for extension of the european patent (deleted)
2022-03-23	A4	Supplementary search report drawn up and despatched	Effective date: 20220217
2022-03-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/4439 20060101ALI20220211BHEP Ipc: A61K 31/4155 20060101ALI20220211BHEP Ipc: A61K 31/42 20060101ALI20220211BHEP Ipc: A61K 31/4152 20060101ALI20220211BHEP Ipc: C07D 231/38 20060101ALI20220211BHEP Ipc: C07D 231/52 20060101ALI20220211BHEP Ipc: C07D 233/88 20060101ALI20220211BHEP Ipc: C07D 401/04 20060101ALI20220211BHEP Ipc: C07D 239/42 20060101ALI20220211BHEP Ipc: C07D 413/04 20060101ALI20220211BHEP Ipc: C07D 263/48 20060101ALI20220211BHEP Ipc: C07D 261/14 20060101AFI20220211BHEP
2023-10-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-11-29	17Q	First examination report despatched	Effective date: 20231027

Publication	Publication Date	Title
EP3464381A4 (fr)	2019-12-11	Composés et méthodes de traitement des maladies trop2 positives
EP3448874A4 (fr)	2020-04-22	Compositions pour le traitement de maladies
EP3448875A4 (fr)	2020-04-08	Compositions pour le traitement de maladies
EP3448987A4 (fr)	2020-05-27	Compositions pour le traitement de maladies
EP3481402A4 (fr)	2020-01-22	Composés, compositions et méthodes de traitement de maladie
EP3675859A4 (fr)	2021-06-30	Composés, compositions et méthodes pour le traitement d'une maladie
EP4010080C0 (fr)	2023-09-27	Composés hétérocycliques destinés à être utilisés dans le traitement du cancer
EP3484504A4 (fr)	2020-07-29	Composés, compositions et méthodes de traitement de maladie
EP3256218A4 (fr)	2018-08-08	Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3790867A4 (fr)	2021-10-13	Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3621973A4 (fr)	2021-10-27	Composés pour la prévention et le traitement de maladies et leur utilisation
EP3655404A4 (fr)	2021-03-31	Composés et leur utilisation pour le traitement d'infections microbiennes
EP3600286A4 (fr)	2020-12-02	Composés et procédés pour le traitement de maladies parasitaires
EP3585786A4 (fr)	2020-08-12	Composés pour le traitement de troubles de stockage du glycogène
IL280570A (en)	2021-03-25	Mini-GDE for the treatment of glycogen storage disease III
EP3504204A4 (fr)	2020-05-27	Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
IL259297A (en)	2018-07-31	Heterocyclic compounds for the treatment of disease
EP3423461A4 (fr)	2020-03-25	Composés de sélénogalactoside pour la prévention et le traitement de maladies associées à la galectine et leur utilisation
EP3846821A4 (fr)	2022-05-25	Polythérapie destinée au traitement d'une maladie hépatique
EP3820477A4 (fr)	2022-07-13	Composés, compositions et procédés pour le traitement d'une maladie
EP3807254A4 (fr)	2022-03-23	Composés hétérocycliques utiles dans le traitement d'une maladie
EP3568137A4 (fr)	2020-05-27	Composés hétérocycliques et utilisation de ces composés
ZA202006886B (en)	2022-07-27	R-fadrozole for use in the treatment of aldostonerism
EP3867266A4 (fr)	2022-07-13	Avexitide pour le traitement de l'hypoglycémie hyperinsulinémique
EP3846843A4 (fr)	2022-06-22	Compositions et procédés de traitement de maladie cardiaque